When was Mindset Pharma founded?

Mindset Pharma was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Mindset Pharma located?

Mindset Pharma is headquartered in Toronto, Canada.

Who is the current CEO of Mindset Pharma?

James Lanthier of Mindset Pharma.

How many employees does Mindset Pharma have?

As of May 31, 2026, the latest employee count at Mindset Pharma is 3622.

Is Mindset Pharma a funded company?

Mindset Pharma is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 09, 2020.

When was the latest funding round of Mindset Pharma?

Mindset Pharma's latest funding was a $***** Post IPO round on Apr 26, 2021, with participation from 0 investor. Its primary sector is Neurology. In Canada, the Neurology sector has seen $179M in funding in 2026 to date.

Where does Mindset Pharma rank among its competitors?

Mindset Pharma ranks 11th amongst 36 active competitors, of which 10 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Psilera, which secured $8.8M in May, 2026.

Who are the top competitors of Mindset Pharma?

Mindset Pharma's top competitors include COMPASS Pathways, MindMed and Gilgamesh. Among them, Psilera secured the most recent funding round in May, 2026.

Mindset Pharma - 2026 Company Profile, Team, Funding & Competitors

Mindset Pharma is a public company based in Toronto (Canada), founded in 2019. It operates as a Developer of psychedelic therapeutics to treat psychiatric disorders. Mindset Pharma has raised an undisclosed amount in funding from Ontario Brain Institute. The company has 36 active competitors, including 10 funded and 14 that have exited. Its top competitors include companies like COMPASS Pathways, MindMed and Gilgamesh.

Company Details

Developer of psychedelic therapeutics to treat psychiatric disorders. The company's lead Compound MSP-1014 is a CNS penetrant used for the treatment of depression, anxiety, addiction, and PTSD. Also, developing other psychedelic drug candidates for multiple indications.

Website: mindsetpharma.com
Social

Key Metrics

Founded Year

2019

Location

Toronto, Canada

Stage

Public

Latest Funding Round

Post IPO, Apr 26, 2021, $*****

Investors

Ontario Brain Institute

Ranked

11^th among 36 active competitors

Employee Count

3,622 as on May 31, 2026

Similar Companies

COMPASS Pathways & 42 more

Exit Details

Public

View Mindset Pharma's full profile

Mindset Pharma got listed on Dec 23, 2020.

Click here to take a look at Mindset Pharma's IPO in detail

Mindset Pharma has raised funding over 2 rounds. Its first funding round was on Nov 09, 2020. Mindset Pharma has 1 institutional investor.

Here is the list of recent funding rounds of Mindset Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 26, 2021	9193412	Post IPO	7448200	9365152	2895649	6833364
Nov 09, 2020	9119109	Seed	6212012	7512551	Ontario Brain Institute	9276691

Access funding benchmarks and valuations. Sign up today!

View details of Mindset Pharma's funding rounds and investors

Mindset Pharma's employee count trend

Mindset Pharma has 3,622 employees as of May 26. Here is Mindset Pharma's employee count trend over the years:

Uncover Mindset Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mindset Pharma include COMPASS Pathways, MindMed and Gilgamesh. Here is the list of Top 10 competitors of Mindset Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Perceptive Advisors, Able Partners & 20 others	66/100
2nd	MindMed 2019, New York City (United States), Public	Developer of psychedelic-based therapies for brain health disorders	-	TR Ventures, K2 HealthVentures & 9 others	58/100
3rd	Gilgamesh 2019, New York City (United States), Series B	Developer of drugs for neuropsychiatric conditions	$152M	Prime Movers Lab, Satori Capital & 18 others	57/100
4th	Cybin 2002, Toronto (Canada), Public	Provider of psychedelic therapeutics for psychiatric disorders	-	Hightrailcapital, Subversive Capital & 10 others	56/100
5th	Delix Therapeutics 2019, Menlo Park (United States), Series A	Developer of therapeutic solutions for the treatment of multiple neurological disorders	$100M	RA Capital Management, Artis Ventures & 22 others	55/100
6th	Psilera 2019, Tampa (United States), Seed	Manufacturer of natural-based medicines for the treatment of mental health illnesses	$11.3M	Iter Investments, What If Ventures & 4 others	48/100
7th	Tryp Therapeutics 2020, Kelowna (Canada), Public	Developer of therapeutic solutions for treating neuropsychiatric disorders & pain	-	-	48/100
8th	Neural Therapeutics 2020, Toronto (Canada), Public	Developer of ethnobotanical drug for neurological disorder	$495K	-	47/100
9th	Psyence 1997, Toronto (Canada), Public	Developer of psychedelic therapeutics for mental health disorders	-	-	47/100
10th	Eleusis 2013, London (United Kingdom), Acquired	Developer of immunomodulatory and neuroprotective medicines	$1.47M	Palo Santo, Noetic Psychedelic Fund & 4 others	47/100
11th	Mindset Pharma 2019, Toronto (Canada), Public	Developer of psychedelic therapeutics to treat psychiatric disorders	-	Ontario Brain Institute	46/100